Recent History (2012-2014)
2012 saw an escalation in activity at the Foundation.
Foundation's board mandates new strategic direction, to develop an international consortium, a comprehensive research strategy and a national team to ultimately raise and manage $20,000,000 per annum for sustainable funding of Australian researchers and clinical trials.
The Brain Cancer Discovery Collaborative (BCDC), launched with a $1,000,000 of funds from Cure Brain Cancer. The BCDC is a centre of excellence in brain cancer research in Australia, facilitating collective research projects and sharing data.
Cure Brain Cancer also co-established the Global Brain Exchange (GBX), by hosting a think-tank to identify sustainable ways to support Australian researchers and develop global collaboration, connecting multiple, like-minded stakeholders around the globe to share knowledge and resources and to develop a model for a global brain cancer research collaborative.
Cure Brain Cancer signed an international agreement wit the US-based Brain Mapping Foundation and Society for Brain Mapping and Therapeutics (SBMT) aimed at breaking new grounds and introducing games changing therapies for brain cancer.
Following on from the March think tank, Cure Brain Cancer was invited to participate in a global brain cancer meeting held in Phoenix Arizona attending by leading scientists and thinkers from across the globe.
Our Walk4Life event, which has been running succesfully for six years, went national for the first time and Australians all over the country got to their feet for brain cancer research.
Cure Brain Cancer attended a special meeting in China to develop Asia Pacific alliances.
We reached a major milestone in our history as we rebranded to become Cure Brain Cancer Foundation; a name more clearly aligned to our mission.
We committed an additional $2.2 million to nine new brain cancer research projects following our 2014 grant round application process.
Together with our partners, we announced funding for Zero Childhood Cancer, a personalised medicine and clinical trial program for children.
Together with Olivia Newton-John, we announced funding for a clinical trial of the immunotherapy drug Duvarlumab in GBM, which will see Australian researchers joining forces with global counterparts.
GBM AGILE was announced to the world, a revolutionary, global adaptive clinical trial brought about by the biggest collaboration in the history of brain cancer research, in which Cure Brain Cancer has played a key role.
The VERTU clinical trial is announced, evaluating a drug called veliparib (a PARP inhibitor), which could enable standard chemotherapy and radiotherapy to more effectively kill cancer cells in all GBM patients.